Skip to content
Myasthenia Gravis News logo Newsletter
Newsletter
  • About MG
    What is myasthenia gravis?
    • Types
    • Causes
    • Symptoms
    • Diagnosis
    • Living with myasthenia gravis
    Treatment
    • Approved treatments
    • Experimental treatments
  • Featured topics
    MGLife360
    • Videos: Coping with change
    • MG and work
    • Myasthenia gravis and fatigue
    • MG medication guide
    • Awareness and advocacy
    • Collaboration with providers
    • MG and pregnancy
    • Exercise and MG
    • MG flare-ups
    • Mental health
    • View all
    Navigating MG
    • Videos: Finding balance
    • Talking to children about MG
    • MG and magnesium
    • MG care plan
    • MG relapses
    • MG infusion center guide
    • Eye health and MG
    • MG Quiz: Know the essentials
    • Support groups and resources
    • Air hunger and MG
    • View all
    Reality of Rare [videos]
    • Managing MG energy
    • Setting MG boundaries
    • MG service dog reactions
    • MG life hacks
    • Sudden MG symptoms
    • Living dreams with MG
    • More
    Video: Parenting with MG
  • News
  • Columns
    Me, My Brother, and MG — Allen Francis
    My Bitter & Best Friend: MG — Sarah Bendiff
    Together — Mark Harrington
    The Whispered Roar — Shawna Barnes
    Archived columns
    • A Good Life with Bad Muscles — Retha De Wet
    • Never Give Up — Bob Kuppler
    • Obstacles Can Excite Creativity — Jodi Enders
    • Positively MG — Megan Hunter
    • Strength in Weakness — Michelle Gonzaba
  • Forums
  • Advocacy partners
  • Provider finder
  • What can we help you find today?

Myasthenia gravis guide to clinical trials

Last updated Aug. 6, 2025, by Agata Boxe
✅ Fact-checked by Patrícia Silva, PhD

What is a clinical trial?
Benefits and risks
Types of MG clinical trials
Where to find
Questions to ask
Additional information

 

Although researchers have made progress with therapies for myasthenia gravis (MG), further work is needed to help manage fatigue, and to improve strength, mobility, and quality of life in people with the autoimmune-related disease.

Scientists continue to explore new treatments through clinical trials, which test whether therapies are safe and effective before they are approved by the U.S. Food and Drug Administration (FDA) or other regulatory agencies

Enrolling in an MG clinical trial can give you access to experimental therapies while helping to advance scientific understanding and treatment options. However, it is key to consult your doctor before deciding whether participation is right for you.

What is an MG clinical trial?

A clinical trial is a carefully designed research study that assesses new ways to treat, manage, or monitor diseases such as MG. It is usually done after lab and animal testing.

MG clinical trials may focus on:

  • reducing fatigue and improving muscle weakness through medication
  • investigating treatments that may reduce autoantibody production
  • studying new therapy delivery methods, such as infusion versus oral
  • assessing tools to better track MG symptom changes and responses to treatment.

Clinical trials for MG typically follow four phases:

  • Phase 1 trials usually test safety and dosage in a small group of participants.
  • Phase 2 trials usually evaluate the effectiveness of treatment while continuing to monitor safety.
  • Phase 3 trials generally compare the new therapy to a placebo or existing standard treatment in a larger group.
  • Phase 4 trials are done after FDA approval to study long-term safety and effectiveness in a real-world setting.

The benefits and risks of MG trials

The severity of your MG symptoms, such as fatigue, muscle weakness, and droopy eyelids, can influence whether you choose to join a clinical trial. However, it is still important to consider both its benefits and risks.

The benefits of MG clinical trials include:

  • early access to promising new treatments
  • a chance to proactively manage your MG
  • an opportunity to contribute to research that could benefit others with MG.

The risks of clinical trials include:

  • potential side effects from new or experimental therapies
  • a possible lack of improvement or worsening of symptoms
  • the possibility of receiving a placebo or standard therapy
  • extra time needed for visits, tests, or travel
  • costs not covered by insurance or the study sponsor.

Types of MG clinical trials

Clinical trials for MG can explore various treatments, including:

  • immunomodulating therapies
  • monoclonal antibody-based treatments for MG
  • medications designed to improve nerve-muscle communication.

Some trials will address refractory, or hard-to-treat, MG, and involve people who do not respond to approved treatments. Other studies will test the use of imaging, digital tools, or biomarkers to better track disease activity.

Many MG trials enroll people with generalized MG, where the disease causes muscle weakness in varying parts of the body. Others may target other MG types, such as ocular MG, which mostly affects the muscles responsible for controlling eye and eyelid movements.

Where to find MG clinical trials

To learn about MG clinical trials, start by talking to your neurologist. As a specialist, your neurologist may be aware of trials at academic centers, hospitals, or research networks, and can inform you whether you’re eligible.

You can find additional information through online resources.

For information about clinical trials in the United States, you can try these websites:

  • ClinicalTrials.gov
  • CenterWatch
  • Myasthenia Gravis Foundation of America
  • National Institutes of Health
  • Research Match.

For trials outside the U.S., these websites may be helpful:

  • EU Clinical Trials Register
  • ISRCTN Registry (UK)
  • World Health Organization
  • Australian New Zealand Clinical Trials Registry.

What to ask before joining an MG clinical trial

If you’re considering participating in an MG clinical trial, asking questions can help you make an informed decision. Consider compiling a list of questions for your MG doctor, the research team, and even yourself as you learn more about the trial process.

There are certain questions you might ask your MG doctor:

  • Am I a good candidate for an MG clinical trial?
  • Are you aware of any current clinical trials for MG that would be suitable for my disease type and symptoms?
  • Would participating in a trial affect my current treatment plan?
  • What are the potential risks and benefits of the trial you may be recommending?
  • What would the trial require in terms of treatment, travel, and time commitment?

Other questions can be asked of the research team:

  • What kind of treatment will the trial be testing, and why do you think it will work?
  • Are there any known side effects, and if so, how can they be managed?
  • Does this study involve a placebo or another MG treatment that is already on the market?
  • What are the odds of receiving a placebo or another MG therapy versus the new treatment?
  • Who will cover the costs of my participation in the trial, and do I need insurance?

Inquiring about costs is especially important. While many trials cover the cost of experimental treatments and related care, some may not. If you’re insured, you can contact your provider to see if the company can cover participation-related expenses.

Finally, consider this list of questions to ask yourself:

  • What do I hope to gain from this trial? Are my expectations realistic?
  • Am I prepared for potential side effects or the possibility of receiving a placebo?
  • Can I manage the time and travel requirements?
  • How may participation affect my daily life and mental health?
  • Am I prepared to handle the emotional impact if the treatment doesn’t work for me?

Additional information about MG clinical trials

Clinical trials for MG can offer access to new treatments, as well as a way to perhaps more actively engage in your own care. However, trial participation may not be suitable for everyone, so carefully considering the potential benefits and risks is crucial.

Consult your doctor before enrolling, and don’t hesitate to ask questions — your voice and initiative matter for managing MG symptoms and planning your future.


Myasthenia Gravis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Clinical trial news

Two hands, a stethoscope, and a handful of oral medications frame a graph marked Clinical Trial that shows positively trending results.
July 15, 2025 News by Lindsey Shapiro, PhD

Switch to Zilbrysq for gMG found safe, effective in clinical trial

Daily treatment with Zilbrysq (zilucoplan) was safe and effective in people with generalized myasthenia gravis (gMG) who were switching from Soliris (eculizumab) or Ultomiris (ravulizumab-cwvz), according to results…

A half-filled liquid medication prescription bottle bears a label reading
May 14, 2025 News by Marisa Wexler, MS

Cartesian launching 2 clinical trials testing Descartes-08 in MG

Cartesian Therapeutics is gearing up for two clinical trials of its cell therapy Descartes-08: the first, a Phase 3 study, will enroll adults with myasthenia gravis (MG), while the second, a…

A bar graph, a pie chart, and an oral prescription medicine bottle are sandwiched between the words
April 10, 2025 News by Marisa Wexler, MS

Long-term benefits seen with Descartes-08 treatment in MG

Treatment with the cell therapy Descartes-08 led to long-term reductions in symptom severity for people with myasthenia gravis (MG) taking part in a Phase 2b clinical trial, according to updated data announced…

A presenter speaks at a white board in front of a group of people.
October 22, 2024 News by Margarida Maia, PhD

Nipocalimab safely eases gMG symptoms in teens: Vibrance trial

Johnson & Johnson’s nipocalimab appears to be safe and to ease symptoms of generalized myasthenia gravis (gMG) in adolescents with antibodies against the acetylcholine receptor, the most common type of MG-causing…

A graph illustrating a clinical trial's results shows two arrows, both moving upward.
May 28, 2024 News by Steve Bryson, PhD

Telitacicept reduces gMG severity in Phase 2 study

Nearly six months of treatment with RemeGen’s telitacicept (RC18) lessened disease activity in adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor, according to data from…

  • 1
  • 2
  • 3
  • 4
  • …
  • 6
  • Next Next
  • Next Next

Recent Posts

  • Live webinar Oct. 23 on managing MG with support and confidence
  • FDA grants orphan drug designation to CNP-106 for gMG
  • The healing power of sleep in my life with MG
  • Daily declarations of perseverance against the unpredictability of MG
  • Blood proteins may predict success of gMG treatments


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

This field is for validation purposes and should be left unchanged.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.